

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: markspencer

Timestamp: Thu Jul 26 15:28:19 EDT 2007

=====

Application No: 10578313

Version No: 1.0

Input Set:

Output Set:

Started: 2007-07-25 09:27:48.523

Finished: 2007-07-25 09:27:49.050

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 527 ms

Total Warnings: 11

Total Errors: 0

No. of SeqIDs Defined: 11

Actual SeqID Count: 11

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)

SEQUENCE LISTING

<110> Genovoxx GmbH
Cherkasov, Dmitry
Hennig, Christian

<120> Macromolecular Nucleotide Compounds and Methods for Using the
Same

<130> 076030-0011

<140> 10578313

<141> 2007-07-25

<150> 10/578,313

<151> 2006-05-04

<150> PCT/EP04/012556

<151> 2004-11-05

<150> 103 56 837.9

<151> 2003-12-05

<150> 103 51 636.0

<151> 2003-11-05

<160> 11

<170> PatentIn version 3.4

<210> 1

<211> 20

<212> DNA

<213> Artificial

<220>

<223> Primer, example 34A, modified on 5 prime-end by Cy3

<400> 1

taatacgcact cactataggg

20

<210> 2

<211> 33

<212> DNA

<213> Artificial

<220>

<223> Template, example 34A

<400> 2

agtttttagtt ttaccctata gtgagtcgta tta

33

<210> 3

<211> 35

<212> DNA

<213> Artificial

<220>

<223> Primer, example 34B, modified at 5 prime -end by Cy3

<400> 3

tttttttttt tttttttttt tttttttttt ttttt 35

<210> 4

<211> 40

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide, modified at 5 prime -end by Cy3

<400> 4

tttttttttt tttttttttt tttttttttt tttttttttt 40

<210> 5

<211> 50

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide, example 34B, modified at 5 prime -end by Cy3

<400> 5

tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt 50

<210> 6

<211> 270

<212> DNA

<213> Artificial

<220>

<223> Polynucleotide with an average length of 270 nucleotides, example 34B

<400> 6

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 120

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 180

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 240

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 270

<210> 7

<211> 50

<212> DNA

<213> Artificial

<220>

<223> Oligonucleotide, example 34C, modified at 3 prime- end by biotin, attached via a TEG-linker

<400> 7
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 50

<210> 8
 <211> 35
 <212> DNA
 <213> Artificial

<220>

<223> Primer, example 35

<400> 8
 tttttttttt tttttttttt tttttttttt tttttt 35

<210> 9
 <211> 31
 <212> DNA
 <213> Artificial

<220>

<223> Oligonucleotide, example 39, modified at 3 prime- end by an amino-group, at 5 prime- end by Cy3

<400> 9
 tttttttttt tttttttttt tttttttttt t 31

<210> 10
 <211> 31
 <212> DNA
 <213> Artificial

<220>

<223> Oligonucleotide, example 30, modified at 3 prime- end by biotin, coupled via TEG-spacer

<400> 10
 tttttttttt tttttttttt tttttttttt t 31

<210> 11
 <211> 30
 <212> DNA
 <213> Artificial

<220>

<223> Oligonucleotide, examples 27 and 32, modified at 3 prime- end by SH-group

<400> 11

tttttttttt tttttttttt tttttttttt

30